CTLA4 and non-small cell lung carcinoma: Additionally, there were 142 and 16 NSCLC patients who showed NDB after treatment with anti-PD-1/PD-L1 and anti-PD1/PD-L1 plus anti-CTLA-4, respectively (Table 1).